Clinical trials: Pneumococcal Infectious Disease
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Bacterial, Pneumococcal Infections
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different…
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Trial name
- NCT05412030
- Testing
- AFX3772, Prevnar 13, Prevnar 20
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants
Phase 1/2, Prospective, Single Center, Randomized, ActiveControlled, Double-Blind, Age De-escalation Study to assess the safety and tolerability of SIILPCV10 administered as a single-dose regimen to healthy Gambian pneumococcal…
- Trial name
- NCT02308540
- Testing
- SIILPCV10, Pneumovax 23, Prevenar 13
- Where
- The Gambia
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- PATH
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- Trial name
- NCT04546425
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 66 sites in Australia, Belgium and 10 more
- Volunteers
- 1,258 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Trial name
- NCT04382326
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis…
- Trial name
- NCT00390910
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Infanrix hexa
- Where
- 8 sites in Greece, Spain
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
This study will evaluate the safety and tolerability and immunogenicity of V114 when administered to 2-month old infants. The primary hypotheses are: 1) V114 is non-inferior to Prevenar 13™ for the 13 shared serotypes between…
- Trial name
- PNEU-PED-EU-1 (NCT04031846)
- Testing
- Rotarix™, Infanrix™ hexa, V114
- Where
- 60 sites in Australia, Belgium and 7 more
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer